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Abstract
Background: Radiation therapy (RT) results in pain relief for about 6 of 10 patients with cancer induced bone pain
(CIBP) caused by bone metastases. The high number of non-responders, the long median time from RT to pain
response and the risk of adverse effects, makes it important to determine predictors of treatment response.
Clinical features such as cancer type, performance status and pain intensity, and biomarkers for osteoclast activity are
proposed as predictors of response to RT. However, results are inconsistent and there is a need for better predictors of
RT response. A similar argument can be stated for the development of cachexia; there are currently no predictors that
can identify patients who will develop cachexia later in the cancer disease trajectory. Experimental and preclinical
studies show that pain, depression and cachexia are related to inflammation. However, it is not known if inflammatory
biomarkers can predict CIBP, depression or development of cachexia.
Methods: This multicenter, multinational longitudinal observational study will include 600 adult patients receiving RT
for CIBP. Demographic data, clinical variables, osteoclast and inflammatory biomarkers will be assessed before start of
RT, and 3, 8, 16, 24 and 52 weeks after last course of RT. The primary aim of the study is to identify potential predictors
for pain relief from RT. Secondary aims are to explore potential predictors for development of cachexia, the longitudinal
relationship between pain intensity and depression, and if inflammatory biomarkers are associated with changes in pain
intensity, cachexia and depression during one-year follow up.
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Discussion: The immediate clinical implication of the PRAIS study is to identify potential predictive factors for a
RT response on CIBP, and thereby reduce non-efficacious RT. Patient benefits are fewer hospital visits, reduced
risk of adverse effects and more individualized pain treatment. The long-term clinical implication of the PRAIS
study is to improve the knowledge about inflammation in relation to CIBP, cachexia and depression and potentially
identify associations and mechanisms that can be targeted for treatment.
Trial registration: ClinicalTrials.gov NCT02107664, date of registration April 8, 2014 (retrospectively registered).
Trial sponsor: The European Palliative Care Research Centre (PRC), Department of Clinical and Molecular Medicine,
NTNU, Faculty of medicine and Health Sciences, Trondheim, N-7491, Norway.
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Background
Cancer induced bone pain (CIBP)
Pain is one of the most frequent symptoms among can-
cer patients [1]. About half of cancer patients with pain
are not adequately treated [2, 3]. Pain and other symp-
toms represent a heavy burden on the patients, their
families and also on the health care system. Bone metas-
tases account for up to 70% of cancer related pain [4, 5].
Cancer induced bone pain (CIBP) often present as a
combination of somatic and neuropathic pain [6]. When
tumor masses expand inside bone it can cause pain by
stretching of the periosteum, fractures or invasion of
sensory nerves [7]. Tumor cells also release pro-
inflammatory cytokines, nerve growth factors and in-
crease oxidative stress in the bone microenvironment.
The alternation of biological substances in the bone
microenvironment influence pain perception by activa-
tion of glia cells, sensitization of somatic nerve endings
and disruption of the normal bone homeostasis with a
balanced osteoclast and osteoblast activity [8]. Secretion
of biological substances from tumor cells may also influ-
ence the central nervous system and trough immune
modulation change perception of pain and the efficacy
of opioids [9].
Prediction of RT response in patients with CIBP
Palliative radiation therapy (RT) is a major treatment
modality for cancer induced bone pain (CIBP), often to-
gether with opioids and co-analgesics [10]. Unfortu-
nately, not all patients experience pain relief after RT.
Complete pain response is reported in about one quarter
of the patients, and partial pain response in 40–60%
[11, 12]. Median time to pain response is 1 to 4 weeks
[13]. RT are in most cases not associated with severe ad-
verse effects, but nausea and vomiting is reported in up to
77% of patients [14], and pain-flares during and after RT
is reported by up to one third of the patients [15, 16].
Diarrhoea, skin reactions, lethargy and tiredness are also
potential adverse effects after RT [11].
Based on a relative high number of patients not
responding to RT, time to treatment effect and the risk
of potential side effects it is important to identify poten-
tial predictors for RT response. Former RT trials have
used different pain assessments and different definitions
for RT response. An international consensus on end-
points in RT trials were first published by Chow et al. in
2002 and updated in 2012 and have resulted in more
comparable RT trials [17, 18]. Two recent papers on ra-
ther large patient materials found that patients with
breast or prostate cancer and higher performance status
were more likely to respond to RT. High baseline pain
scores, the use of morphine, absence of visceral metasta-
ses and younger age were also associated with RT re-
sponse in one out of the two papers [19, 20].
Imaging techniques may also be helpful to predict
RT response. Two studies have demonstrated that low
uptake on FDG PET-CT before RT predicted better
RT response [21, 22]. MRI have also been proposed
to predict RT response, but the published results are
so far inconsistent [23, 24]. In addition both PET and
MRI is time and economically difficult to establish as
routine care. Biomarkers such as urinary osteoclast
markers have been proposed to predict RT response
in patients with bone metastases [25, 26], but this as-
sociation is not present in all trials [27]. Elevated
C-reactive protein (CRP) levels are related to more
advanced disease in cancer patients that undergo pal-
liative RT, but as far as we know no studies demon-
strate a relationship between the level of CRP or
other inflammatory markers and RT response in pa-
tients with CIBP [28]. Previous published literature
on clinical predictors for response to RT has also no
information about radiographic appearance of metas-
tases like sclerotic/osteolytic metastases, soft tissue
expansion outside bone, other cancer related symp-
toms or biomarkers as potential predictors.
Thus, there is still not enough information to pre-
dict which patients who are likely to respond poorly,
and consequently should not receive RT. To identify
patients who have increased likelihood of successful
analgesia from palliative RT would improve cancer
pain management.
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Cancer related symptoms and the role of inflammation
In recent years there has been an increased interest
among researchers to understand the correlation be-
tween the immune system and development of cancer
and cancer-related symptoms. Inflammation is present
in the majority of patients with advanced cancer [29],
and it is therefore difficult in cross sectional studies to
establish if inflammation is simply associated with sever-
ity of the cancer disease, or whether inflammation itself
elicits symptoms and can be a target to reduce symp-
toms like pain, depression or cachexia [30].
Cancer induced bone pain and the role of inflammation
Based on results from pre-clinical studies several inflam-
matory mediators are proposed to play an important role
in CIBP. The pro-inflammatory interleukin (IL)-1β, IL-6
and tumor necrosis factor (TNF)-α are associated with
nociception in animal models of bone cancer [31, 32].
Other inflammatory mediators, including chemokines
such monocyte chemoattractant protein (MCP)-1, macro-
phage inflammatory protein (MIP-1)α, and the anti-
inflammatory cytokine transforming growth factor (TGF)β,
are upregulated in animal models of bone metastases, and
receptors for cytokines are also present on the osteoclast
surface. The release of inflammatory cytokines from
tumor cells may therefore contribute to osteoclast ac-
tivation with CIBP as a consequense [8, 33]. Some
studies have demonstrated a potential role of inflam-
mation (CRP, IL-6) for general cancer pain [34–36].
but as far as we know there are no published clinical
trials on inflammation in relation to CIBP.
Development of cachexia and the role of inflammation
Up to 80% of patients with advanced metastatic cancer
develop cachexia, and approximately 20 % of cancer
deaths are attributed to cancer cachexia [37]. Cancer
cachexia has a significant impact on patient morbidity as
these patients often have reduced physical function, in-
creased fatigue and psychosocial distress. According to a
recent international consensus cachexia has been de-
fined as a multifactorial syndrome characterized by an
ongoing loss of skeletal muscle mass (with or without
loss of fat mass) that cannot be fully reversed by conven-
tional nutritional support and leads to progressive func-
tional impairment [38]. In the consensus document,
cachexia is described as a trajectory from early cachexia
to late cachexia, and treatment should be assigned to pa-
tients according to the different stages. A longitudinal
observational study is required to establish which factors
predict both the cachexia syndrome and late cachexia.
The complete pathophysiology behind cachexia is still
unclear. Most studies on molecular mechanisms have
been performed on different animal models; studies in
humans are scarce. Anemia, low serum albumin and
increased inflammatory biomarkers such as CRP, TNF-α,
soluble TNF-receptor 1 (sTNF-R1), IL-1, IL-6 and inter-
feron (IFN)-gamma are observed in patients with cach-
exia [39]. Inflammatory markers such as TGFβ involved
in development of bone metastases is probably also im-
portant in development of cachexia [40]. However, sys-
temic inflammation is seen in a majority of patients with
cancer, and not all of them develop cachexia therefore as
for pain longitudinal studies are needed.
Depression in patients with advanced cancer and the role
of inflammation
Depression disorder contribute to reduced quality of life
in patients with advanced cancer [41]. Depression dis-
order is common among cancer patients with a preva-
lence that varies from 5 to 30% between studies [42]. A
particular challenge for assessment of depression in pa-
tients with advanced cancer is the somatic depression
symptoms (fatigue, psychomotor retardation, appetite
disturbance and sleep disturbance) which constitute 4
out of 9 diagnostic criteria for depression disorder. In
patients with advanced cancer the somatic depression
symptoms can result from depression, the cancer, treat-
ment effects, or a combination of these factors [43].
In a cross-sectional study that also controlled for dis-
ease load, we demonstrated that by only using the 5 psy-
chological depression symptoms for defining depression
disorder, we could circumvent the challenge of the over-
lap between the somatic depression symptoms and
symptoms of the cancer [44] [45]. However, our study
was cross-sectional thus limiting the possibility to assess
causality [44]. Studying the development of depression
disorder and each of the depression symptoms over time
with control for disease and treatment(s) can provide
evidence-based guidance on how to best assess depres-
sion in patients with advanced cancer.
Patients with advanced cancer and depression disorder
have more somatic symptoms including pain compared
to non-depressed patients, but no appropriately designed
studies to examine a possible causal relationship have to
our knowledge been published. Clinically, a common ob-
servation is that long-lasting pain is associated with
increased levels of depression symptoms. Still the direc-
tion of causality is not established and might be bidirec-
tional. The relation between pain and depression has to
be studied in a longitudinal design in order to better
understand how they are related.
Behavior corresponding to the depression symptoms,
such as lowered mood, anhedonia, fatigue, sleep and ap-
petite alterations, are also observed as a response to in-
fections in mammals and then termed sickness behavior.
Sickness behavior has been recognized as a symptom
cluster that is associated with pro-inflammatory cytokine
activation [46]. In non-cancer patients depression disorder
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has been linked to inflammation and oxidative stress [47].
Meta-analyses have demonstrated that IL-6, TNF, and
CRP are elevated in non-cancer patients with depression
disorder [48]. A limited number of studies have demon-
strated increased levels of cytokines (IL-6, IL-8,TNFα) in
cancer patients with depression [49, 50]. These findings
need verification in studies using a validated measure of
depression and controlling for disease and other factors
known to affect the inflammatory response.
The palliative radiotherapy and inflammation study (PRAIS)
As cancer treatment develops, a wider range of treat-
ment options are available to each patient, and the need
for tools to determine treatment response arises to select
the right individual treatment. The primary aim of
the PRAIS study is to combine clinical and biomarker
predictors to predict the response to RT for patients
with CIBP.
The availability and indications for new cancer thera-
peutics that modulates the immune system in order to
delay development and even cure cancer have increased
the last years, and a better understanding of the role of
systemic inflammation in relation to cancer and cancer
associated symptoms are of interest when the field of
immunotherapy develops. To better understand com-
plexity of systemic inflammation one need to extrapolate
knowledge from pre-clinical studies to clinical studies
with a robust study design. Secondary aims of the PRAIS
study are, therefore, in a longitudinal study to explore
the relationship between cancer related symptoms and
inflammatory biomarkers during a one-year follow up.
Methods
Design
A multicenter, international longitudinal observational
study of patients commencing palliative RT for CIBP.
Study objectives
The primary aim of the PRAIS study is to investigate
clinical and biomarker predictors of pain response after
palliative RT for CIBP. In the secondary analyses of this
longitudinal study we will explore association between
inflammation and pain intensity, cachexia, and depres-
sion in patients with CIBP that undergo palliative RT,
factors associated with development of cachexia in
one-year follow up and correlation between pain inten-
sity and depression (Fig. 1).
Study population
Patients to be screened for participation
All patients admitted to palliative RT for bone cancer
pain is eligible for screening.
Inclusion criteria
 Verified cancer diagnosis, including hematological
malignancies (based on radiological, histological,
cytological or operative evidence)
 Bone metastases verified either by x-ray, bone scan,
computer tomography (CT) or magnetic resonance
imaging (MRI)
 Patients that are about to undergo RT with palliative
intent for painful bone metastases
 RT to be administered within 1 week after baseline
observations are obtained
 Age ≥ 18 years
 Patient able to comply with trial procedures
Exclusion criteria
 Pathological fracture in long bones
 Patients not consenting to participate in the study
 On-going RT or RT administered within the last
4 weeks
 Patients who are not able to follow the trial
procedures
 Previous participation in this study
Measurements
Timeline
The patients will be assessed at baseline and 3, 8, 16, 24
and 52 weeks after RT.
Clinical variables
At inclusion the following information will be collected
(variables included as independent variables in the pri-
mary analyses are denoted with an asterisk): Age*, gender*,
ethnicity, height, comorbidity* (Charlson Comorbidity
Index) [51], Karnofsky performance status* [52], living
situation, educational level, alcohol use, smoking status*,
type of department (palliative care unit, surgical ward,
general oncology ward, out-patient clinic, other), onco-
logical history related to the current cancer disease (tumor
diagnosis*, time since cancer diagnosis*, presence of me-
tastases other than bone*, osteolytic metastasis at each
planned site for RT*, soft tissue expansion at each planned
radiation site*, previous and on-going anti-cancer treat-
ment: (RT, surgery, chemotherapy, hormonal treatment,
other interventions – for the primary analyses current
oncological treatment other than RT (Y/N)*), planned RT
(fractions*, total dose* and anatomical region; narrow to
radiation location in weight bearing bone (Y/N) for the
primary analyses*, re-irradiation, previous pain treatments
(duration of opioid treatment and previous unsuccessful
trials with other opioids) and medications and doses for
the previous 24 h (for the primary analyses we will include
opioid dose in oral morphine equivalents last 24 h*and
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steroids*). In addition, an objective measurement of lean
body mass, measured by CT scan of L3 and/or Th4 verte-
brae will be performed at baseline.
At both baseline and at all follow-up visits the follow-
ing self-reports will be collected: Health related quality
of life (EORTC QLQ-C15 PAL) [53] (for the primary
analyses trouble sleeping*, nausea* and constipation* will
be included as variables), nutritional status (PG-SGA)
[54], weight, overall and site specific average and worst
pain last 24 h (BPI) [55] (for the primary analyses “worst
pain last 24h”*), pain at rest and at movement from each
planned irradiated site [56] (for the primary analyses we
will use the variable that reflects worst pain at the irradi-
ated site at baseline*) and depression* (PHQ9) [57].
Specific questions related to episodic pain* and self-re-
port neuropathic symptoms and signs* (LANSS) [58] will
be asked at baseline and after 3 and 8 weeks.
Data on history of hospitalizations, changes in med-
ications, new cancer treatment, treatment for hyper-
calcemia, new pathological fractures or spinal cord
compression since last visit will be obtained at all
follow-up visits (Table 1).
Blood samples
Standard clinical chemistry will be obtained at all visits
and analyzed at the local laboratory in each study center.
Full blood for genetic analyses is obtained at baseline
and serum for analyses on biomarkers is obtained at all
visits. The serum samples will be centrifuged at room
temperature at 2200 g for 10 min, frozen within 1 hour
and stored at − 80 degrees Celsius until analyses. A
Multiplex cytokine assay (Bio-Plex Pro™ Human Cyto-
kine Plex-27 Assay, Bio-Rad Laboratories, Hercules, CA)
will be carried out to analyse inflammatory biomarkers.
Cytokines involved in bone remodelling will be analysed
by EIAs using matched antibodies from R&D Systems.
High-sensitivity CRP will be analysed on a MODULAR
platform (Roche Diagnostics, Basel, Switzerland.) For pa-
tients where collection of blood samples at follow-up is
not possible (i.e. due to travelling distance from study
center), the clinical data are obtained, and participation
is allowed without the collection of follow-up blood
samples (Table 2).
Power consideration
The sample size is based upon the primary outcome; re-
sponse to RT for pain [18]. The analyses plan includes
up to 29 independent clinical variables (see previous sec-
tions for variables marked with an asterisk.) A full statis-
tical estimate of sample size requires knowledge of the
variance-covariance matrix, which was not available at
the planning stage of this study. Therefore, the widely-
used rule of thumb of 10 x number of variables was
adopted. This reasoning resulted in a sample size of 290.
Based upon experience, interactions will arise which in-
creases the needed number of patients, and up to 20% of
patients were expected to be lost to follow-up. To ac-
count for this, the number of needed patients was set to
600. The original protocol plan was to include a valid-
ation sample of 1/3 of patients resulting in a total num-
ber of 1000 included patients. But because of slow
recruitment, we had to close the study after 600 re-
cruited patients, and the analyses will therefore be per-
formed without the planned validation sample.
Trial centers
The trial centers are St. Olavs University hospital,
Trondheim, Norway; Oslo University Hospital, Oslo,
Fig. 1 Study objectives with Research Questions (RQ)
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Norway; Ålesund Hospital, Ålesund, Norway; Fonda-
zione IRCCS Istituto Naxionale dei Tumori, Milan, Italy;
Istituto Scientifico Romagnolo per lo studio e la cura dei
tumori (IRST), Meldola (FC), Italy; Hospital Universitari
Arnau de Vilanova, Lleida, Spain; Castle Hill Hospital,
Cottingham, United Kingdom.
Outcome and statistical analyses
For all planned analyses baseline data will be presented
with descriptive statistics; continuous variables as mean
with standard deviation and categorical variables as fre-
quency with percentages. A detailed overview of re-
search questions and statistical analyses are described in
the following section. All analyses will be performed
using SPSS v 23 (IBM Corp. Armonk, NY) and STATA v
16 (Stata Corporation LP; College Station, TX, USA).
Research question 1: Which are the clinical predic-
tors and biomarkers predictors of pain response to pal-
liative RT for CIBP?
Objective: To obtain demographic, clinical data and
biomarkers before start of RT and compare with RT
response for pain in order to develop a classification sys-
tem relevant for predicting RT response.
Outcome: Primary endpoint is response to RT defined
as at pain reduction of worst pain score of two or more
at the treated site on the 11-point NRS together with no
increase in analgesic intake, or a reduction in opioid in-
take of at least 25% from baseline without an increase in
worst pain score at the treated site [18]. Patients with
two or more radiation locations are defined as re-
sponders if they respond in one of the included sites. Pa-
tients who die before the first assessment (3 weeks after
RT), will be defined as non-responders because these pa-
tients have not benefited from RT. Patients with missing
data on outcome measurements including pain intensity
at the treated site or the use of analgesic medications
will not be included in the analyses.
Statistical method: Clinical variables (see previous
chapter) and CRP will be included in a multivariate lo-
gistic regression model to predict potential factors for
response to RT. The model will be adjusted by study
centre. Regression diagnostics will be performed for all
Table 1 Flow chart for registrations
Time of assessment
Inclusion 3 W 8 W 16 W 24 W 1 YR
Screening for inclusion X
Demographics, cancer history, planned RT, previous pain therapy X
New cancer related incidents X X X X X
Current use of medications X X X X X X
Weight X X X X X X
Performance status X X X X X X
CT scans for body composition (if available) X X X X X X
PG-SGA X X X X X X
Pain registrations X X X X X X
QLQ-C15 PAL X X X X X X
LANSS X X X
Episodic pain questions X X X
PHQ9 X X X X X X
Blood samples for clinical chemistry X X X X X X
Blood samples for biomarkers X X X X X X
Blood samples for genetics X
Table 2 Overview of blood samples obtained at all visits
Clinical chemistry Hemoglobin, white blood cells, differential white cell count, platelets, creatinine, urea, bilirubin, potassium,
sodium, chloride, total calcium, phosphate, magnesium, CRP, albumin, triglycerides, vitamin-D
Inflammatory biomarkers High-sensitivity CRP, IL-1β, IL-1, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8/CXCL-8, IL-9, IL-10, IL-12 (p70), IL-13,
IL-15, IL-17, basic fibroblast growth factor (bFGF), granulocyte colony-stimulating factor (G-CSF),
granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-gamma (IFN-ɣ), eotaxin/CCL11,
IFN-ɣ-inducible protein (IP-10)/CXCL10, MCP-1)/CCL2, MIP-1α/CCL3), MIP-1β/CCL4, regulated on activation,
normal T-cell expressed and secreted (RANTES)/CCL5, TNF, platelet-derived growth factor (PDGF), and vascular
endothelial growth factor (VEGF).
Biomarkers involved in bone remodelling RANK-ligand (RANKL), Osteoprotegerin (OPG) and Notch Ligands: DLL1 and Periostin.
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analyses adding interactions terms if necessary. Signifi-
cant variables from the multivariable model will be pre-
sented as a response-score to determine the likelihood
of response to RT. Second, we will perform analyses on
inflammatory biomarkers and bone biomarkers corre-
lated with response to RT. Only inflammatory bio-
markers and bone biomarkers with levels of serum
concentrations above the detection threshold and which
have a variability between measurements will be ana-
lysed with a multivariate logistic regression model with
response to RT as the dependant variable. Finally, an in-
tegrated regression model with response to RT including
both the significant clinical variables and significant bio-
logical biomarkers will be conducted if appropriate
based on results from the previous analyses.
Research question 2: Which inflammatory bio-
markers are associated with change in pain intensity in
patients with CIBP?
Objective: To investigate the correlation between pain
intensity and inflammation. Patients included in the
PRAIS study all have CIBP and will receive a stan-
dardized intervention expected to give pain relief in
about 60% of the patients. This study can explore if
there is a longitudinal relationship between changes
in pain intensity and the detected level of inflamma-
tory biomarkers.
Outcome: Serum concentrations of inflammatory bio-
markers as described above associated with changes in
pain intensity as measured by average pain intensity and
worst pain intensity last 24 h (NRS 0–11) for a max-
imum of 1 year follow-up.
Statistical method: Longitudinal data analysis with re-
peated measurements using a liner mixed effect model
or generalized estimating equation (GEE).
Research question 3: Which inflammatory substances
are associated with cancer cachexia?
Objective: To gain insight into the role of inflamma-
tion in cancer cachexia.
Outcome: Cachexia is defined as a) weight loss > 5%
over past 6 months (in absence of simple starvation); or
b) body mass index (BMI) < 20 and any degree of weight
loss > 2%; or c) appendicular skeletal muscle index con-
sistent with sarcopenia (males < 7 26 kg/m2; females <
5 45 kg/m2) and any degree of weight loss > 2% [38].
Cachexia severity is assessed as degree of weight loss
and EORTC QLQ C15 PAL physical function and appe-
tite loss.
Statistical method: Fist, we will perform a cross-sec-
tional analysis in the baseline parameters using a logistic
regression with cachexia as outcome, and the various in-
flammatory markers as explanatory variables. Second,
we will investigate the association between changes in
inflammatory markers over time and cachexia severity
using mixed linear modelling.
Research question 4: Which inflammatory substances
are associated with depression in cancer patients?
Objective: To explore the associations between serum
concentrations of inflammatory substances and depression.
Outcome: Depression is measured by the PHQ-9 ques-
tionnaire [57]. The PHQ-9 includes 9 items identical to
the diagnostic criteria (i.e. the depression symptoms) for
depression disorder. For the purpose of these analyses
we will use depressive disorder as defined by the PHQ-9
recommended sum score calculation, and symptom by
symptom in the PHQ-9 score in associations of serum
concentrations of inflammatory biomarkers during a
period of 1 year form inclusion.
Statistical method: We will use repeated measure-
ments and a linear mixed effect model to perform the
analyses.
Research question 5: Which are the clinical predic-
tors and biomarker predictors of development of cach-
exia in patients with metastatic cancer disease?
Objective: To obtain demographic and clinical data
and biomarkers in a homogenous population of patients
with metastatic cancer, and within a prospective, longi-
tudinal follow-up study observe which factors predicting
the development of severe cachexia during one-year
follow-up.
Outcome: Cachexia is defined as for research question 3.
Statistical method: As the purpose is to evaluate devel-
opment of cachexia, only patients without cachexia at
baseline will be included in this analysis. A Cox regres-
sion will be used to evaluate baseline predictors of cach-
exia development.
Research question 6: What is the relationship be-
tween pain reduction and depression in patients receiv-
ing RT for CIBP?
Objective: RT is expected to reduce pain in a substan-
tial number of patients. This creates a possibility to
study the relationship between depression and pain lon-
gitudinally in an experimental-like design in which one
variable (pain) is manipulated and the effect on another
related variable (depression) is studied.
Outcome: Depression is measured as for Research
question 4.
Statistical method: Longitudinal analyses with repeated
measurements analyzed with a linear mixed effect model.
Ethics
A signed consent will be obtained from all participants
by an investigator at each site. The study will be carried
out in accordance with ICH GCP and the World Med-
ical Association Declaration of Helsinki (1964) and its’
revisions (Tokyo 1978, Venice 1983, Hong Kong 1989,
South Africa 1996 and Edinburgh 2000). The study is
approved by The Regional Committee for Medical and
Health Research Ethics, REC Central Norway, and by
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the regulatory authorities at each trial site. If modifications
to the protocol, amendments will be applied for to the re-
gional ethics committee and after approval distributed to
all local study investigators.
RT is indicated and will be given regardless of whether
the patients choose to participate in the study or not.
Thus, study participation means that patients consent to
report symptoms and have their blood drawn. The vol-
umes of blood samples are limited (less than 50 ml) and
give no extra risk for anemia. Thus, the study includes
no interventions that increase the risk for the patients.
Data are handled anonymously. The database used for
analyses only identify each patient by a study number.
The linkage between study number and patient identity
is in a document and / or memory stick stored in a safe
at each study center.
Organizational issues
A Trial Steering Group will oversee the running of the
trial. Members of the trial steering group include the
chief principal Investigator, the principal Investigators of
each centre, the Clinical Trial coordinator, and the trial
statistician. After completion of the inclusions the Trial
Steering Group will consists of the chief principal inves-
tigator, the principal investigators at all sites including
100 patients or more, and the trial statistician.
The coordinating centre will administer the study.
This includes development and administration of Case
report forms (CRFs), monitoring of data quality and
preparation of the final study report. (CRFs) will be sup-
plied by the coordinating centre. Specific queries about
data will be addressed to the clinical trial coordinator at
each study centre.
The results will be published in peer-reviewed jour-
nals. Authorship is based upon the Vancouver rules. All
manuscript will be prepared by the researchers. The trial
steering group will make decision related to use of data
for publication. The principal investigator has access to
all data. Access to researchers will be decided based
upon the actual need for access relevant for analyses.
Access to anonymously participant-level data set will be
supplied depending on the journal policies.
Discussion
Clinical trials in cancer are mostly carried out to evaluate
and compare different treatment strategies, medications
and interventions. Whiles the effect of RT to treat CIBP is
well documented, there is limited information about which
characteristics that differs among responders versus
non-responders. To achieve reliable predictors for treat-
ment response, studies with large patient materials that ob-
tain follow-up visits are needed. In this study, detailed
clinical information, inflammatory and bone biomarkers
will be collected before RT. These are all data and analyses
that could be included in routine clinical practice to better
select patients likely to have RT response. This can reduce
the administration of non-efficacious RT. Patients will
benefit from not spending time on futile treatment and not
risking adverse effects related to RT as well as not delaying
alternative pain treatments.
Our research group has in the last decade published
several papers on cancer pain and the relationship be-
tween pain and other cancer symptoms to improve cancer
pain classification [59–61]. International collaboration
have also developed the Edmonton classification for can-
cer pain [56, 62]. The PRAIS study will include a large
cancer patient population with advanced, but not ter-
minal, cancer disease that will be used to investigate which
clinical characteristics and biomarkers are associated with
other cancer related symptoms. We will explore the longi-
tudinal associations for pain, depression and cachexia with
clinical characteristics, and biomarkers.
The investigation of the role of inflammation in re-
spect to RT response for patients with CIBP and other
cancer related symptoms like pain intensity, depression
and cachexia is of a more explorative character. Current
literature is mostly based on pre-clinical studies that
needs to be investigated further in human studies. This
study will include patients who all have on-going CIBP,
which is a more homogenous population than usually
seen in cancer pain studies. The patients will receive a
standardized intervention expected to give pain relief in
about 60% of the patients, and the study is therefore a
unique possibility to identify which inflammatory sub-
stances that are associated with changes in cancer pain
intensity. Improved knowledge about the pathophysi-
ology of bone cancer pain and the role of inflammation
can identify potential targets for therapy. The longitu-
dinal design of the study also makes it possible to study
the relationship between inflammation and symptoms of
depression and development of cachexia. If biological
factors are detected they could be used to identify which
patients who could benefit from therapy directed to-
wards hindering or delaying the development of severe
cachexia or treatment of depression in cancer patients.
Expected limitations
As for all studies on palliative cancer patients we expect the
number of drop-outs and missing data to be relatively high.
A reason for drop-out before evaluation of treatment re-
sponse may be that the patients are too sick or because of
high symptom burden. These patients cannot be included
in the predictive analyses as they are not missing at random
and may bias the results. The patient inclusion is also for
practical reasons not consecutive and the sample size of
600 do not allow for a validation sample analyses. Also, in
order to assess the adverse effects from RT, a day-to-day
evaluation of symptoms after RT would have given
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important information but were not performed in order to
simplify data collection for the patient population.
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